Viking’s VK2809 looks at least as good as Madrigal’s MGL-3196 in liver disease – but investors should be careful of making comparisons.
A partial interim trial success could give GKT831 a new lease of life in liver diseases but full data, due next year, will be watched closely.
Trailing the leaders in amyloidosis and Nash, the respective small caps Eidos and Conatus look to mid-stage trial readouts to demonstrate their relevance.
Genkyotex hopes for a reboot with upcoming data on its previously failed lead project, GKT831, in primary biliary cirrhosis.
Positive phase II data delight investors, but Madrigal Pharmaceuticals leads in the race to market.
It’s time for Viking, a Nash player that has climbed in tandem with one of its biotech peers, to prove itself.
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Nash, the one-time favourite therapy area for biopharma speculators, is back.